Additionally, an increase in miR-143-3p and subsequent inhibition of insulin receptor substrate 1 (IRS1) may lead to the initiation of NASH via the development of insulin resistance and hyperglycemia in the liver [130]. This evidence concerns the gene IRS1 and metabolic dysfunction-associated steatohepatitis.